Table III. Clinical trials with recombinant allergens, recombinant allergen derivatives and synthetic allergen-derived peptides.
| Molecules/approximate timeframe | Description of the vaccine | Study design and clinical trial number | References |
|---|---|---|---|
| AllervaxCAT, 1996-1999 | Two Fel d 1-derived peptides of 27 amino acids | SCIT, DBPC | 117, 118, 119 |
| Bet v 1 trimer, Bet v 1 fragments, 2000-2001 | Hypoallergenic recombinant derivatives of Bet v 1 | Phase II, SCIT/DBPC | 24 |
| rPhl p 1, rPhlp 2, rPhlp 5a + b, rPhl p 6, 2002-2013 | Recombinant grass pollen allergen cocktail | Phase II, SCIT/DBPC NCT00671268, NCT00309036 | 25 |
| Folding variant of Bet v 1, 2002-2013 | Hypoallergenic recombinant folding variant of the major birch pollen allergen (rBet v 1-FV) | Phase III, SCIT/DBPC NCT00266526, NCT00554983, NCT00841516 | 28, 120 |
| rBet v 1, 2002-2008 | Comparison of rBet v 1 with nBet v 1 and birch pollen extract for SCIT in birch pollen allergic patients | Phase II, SCIT/DBPC NCT00410930 | 26 |
| rBet v 1 tablets, 2006-2013 | r Bet v1 administered as sublingual tablets in birch pollen allergic subjects | Phase II, SLIT, DBPC NCT00901914 NCT00396149, NCT00889460 | 121 |
| ILIT with MAT-Fel d 1, 2008-2010 | Intralymphatic immunotherapy for cat allergy | Phase I, NCT00718679 | 122 |
| Ara h 1, Ara h 2, and Ara h 3, 2009-2013 | Rectal application of E. coli-encapsulated, recombinant modified peanut proteins Ara h 1, Ara h 2, and Ara h 3 | Phase I, safety study NCT00850668 | 123 |
| Fcγ1-Fel d1 fusion protein, 2011-2014 | Intradermal, human Fcγ1-Fel d 1 fusion protein | Safety study, NCT01292070 | 124 |
| BM 32, 2012-2017 | Hypoallergenic recombinant vaccine for immunotherapy of grass pollen allergy consisting of derivatives of the 4 major grass pollen allergens, phl p 1, Phl p 2, Phl p 5, and Phl p 6 | Phase IIa and 2 phase IIb studies, SCIT/DBPC NCT01350635, NCT01538979, NCT02643641 | 30, 31 |
| ToleroMune Cat, 2012-2016 | Fel d 1-derived synthetic peptides for induction of tolerance in cat allergic patients | Phase III, intradermal/DBPC NCT01620762 | 125, 126 |
| AllerT, 2012-2015 | Bet v 1-derived contiguous overlapping peptides | Phase IIb, SCIT/DBPC NCT01720251, NCT02143583, NCT02271009 Long-term follow-up of a phase IIb study AN004T |
29, 127, 128 |
| Sublingual immunotherapy of birch pollen-associated apple allergy, 2012-2016 | Recombinant Mal d 1 | Single-center, double-blind, placebo-controlled explorative study NCT01449786 | 129 |
| FAST-Fish, 2013-2015 | SCIT for fish allergy based on the subcutaneous application of mutated parvalbumin (rCyp p 1) | Phase IIa, NCT02017626 | 109 |
| ToleroMune Grass, 2014-2016 | Short peptides from grass pollen allergens | Phase IIb/III started intradermal/DBPC NCT02795273, NCT02161107 | |
| ToleroMune HDM, 2014-2016 | Short peptides derived from house dust mite allergens | Phase II, intradermal/DBPC NCT02150343 | |
| ToleroMune Ragweed, 2014-2016 | Short peptides from Amb a 1 | Phase II, NCT02061709, NCT02396680 |
DBPC, Double-blind, placebo-controlled; HDM, house dust mite; SCIT, subcutaneous immunotherapy.